Rafferty Asset Management LLC Has $483,000 Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Rafferty Asset Management LLC cut its holdings in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 54.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,255 shares of the company's stock after selling 60,967 shares during the quarter. Rafferty Asset Management LLC's holdings in MiMedx Group were worth $483,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MDXG. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group in the 4th quarter worth $28,000. Van ECK Associates Corp acquired a new position in MiMedx Group in the fourth quarter valued at about $40,000. Tower Research Capital LLC TRC grew its position in shares of MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares during the period. AlphaQuest LLC bought a new stake in shares of MiMedx Group in the 4th quarter valued at about $88,000. Finally, Koss Olinger Consulting LLC acquired a new stake in shares of MiMedx Group in the 4th quarter valued at approximately $100,000. Institutional investors and hedge funds own 79.15% of the company's stock.

MiMedx Group Stock Down 1.8%

MDXG traded down $0.12 during trading on Wednesday, reaching $6.65. The company had a trading volume of 109,451 shares, compared to its average volume of 690,554. The company has a market cap of $981.63 million, a P/E ratio of 12.11 and a beta of 1.85. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The business's fifty day moving average price is $7.03 and its 200 day moving average price is $8.16.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. Equities analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insider Activity at MiMedx Group

In other MiMedx Group news, CEO Joseph H. Capper acquired 200,000 shares of the business's stock in a transaction dated Friday, May 2nd. The stock was bought at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the transaction, the chief executive officer now directly owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares of the company's stock, valued at $3,859,237.20. This represents a 14.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 144,018 shares of company stock valued at $1,130,312. Insiders own 1.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wall Street Zen downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.